G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
57 hedge funds and large institutions have $270M invested in G1 Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 8 reducing their positions, and 3 closing their positions.
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
200% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 8
36% more funds holding
Funds holding: 42 → 57 (+15)
7% less capital invested
Capital invested by funds: $289M → $270M (-$19.5M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.4M |
| 4 |
BlackRock
New York
|
+$8.52M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$5.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$54.3M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$4.98M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$548K |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$150K |
| 5 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$132K |
GTHX Hedge Fund Activity: Q4 2017 in Review
57 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q4 2017, worth a combined $270M — down 6.7% from $289M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GTHX positions and 3 closed out — a net gain of 15 holders — while 24 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $34.1M. The largest seller was RA Capital Management, cutting an estimated $54.3M.
- 57 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q4 2017, up from 42 in Q3 2017.
- Funds reported $270M of G1 Therapeutics, Inc. Common Stock stock for Q4 2017, down 6.7% quarter-over-quarter.
- 18 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q4 2017 and 3 closed out, a net change of +15 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q4 2017 was Fidelity Investments, an estimated $34.1M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q4 2017 was RA Capital Management, an estimated $54.3M sold.
Based on aggregated 13F filings for Q4 2017.